Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

RBC Capital Markets reiterates 'buy' rating on Barclays

(Sharecast News) - Analysts at RBC Capital Markets took a fresh look at Barclays on Monday following the bank's Q424 earnings, reiterating its 'outperform' rating and 340.0p target price RBC Capital Markets said its FY26 adjusted pre-tax profit estimates remain broadly unchanged, as slightly lower income and higher cost estimates were offset by lower impairment charges.

On a divisional basis, RBC Capital said a small increase in pre-tax profit estimates for Barclays Investment Bank, as well as a smaller loss in its Head Office, were largely offset by lower US Consumer Bank estimates.

The Canadian bank also updated its structural hedge modelling and now estimates structural hedge income of £6.1bn/£6.6bn/£6.8bn in FY25/FY26/FY27, respectively.

"Our numbers assume that: i) relative to Q4, BARC's hedge notional falls c. £2bn in 2025 and remains broadly stable thereafter; and ii) 5yr swap rates average 3.7%/3.1%/3.0% in 2025/26/27 (BARC assumption of c.3.5% in FY25), remaining broadly stable at c.3% until 2030," said RBC.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.